Laura Layos

Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma

Eric Van Cutsem, Margaret A. Tempero, Darren Sigal et al. · Journal of Clinical Oncology · 2020 · 446 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

James J. Harding, Jia Fan, Do‐Youn Oh et al. · The Lancet Oncology · 2023 · 247 citations · Full text

Medicine, Oncology, Pharmacology +10

Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway

Vicenç Ruiz de Porras, Sara Bystrup, Anna Martínez‐Cardús et al. · Scientific Reports · 2016 · 136 citations · Full text

Medicine, Oncology, Pharmacology +17

HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA).

Margaret A. Tempero, Eric Van Cutsem, Darren Sigal et al. · Journal of Clinical Oncology · 2020 · 114 citations

Medicine, Oncology, Pharmacology +16

UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy

Eva Martinez‐Balibrea, Albert Abad, Anna Martínez‐Cardús et al. · British Journal of Cancer · 2010 · 88 citations · Full text

Medicine, Oncology, Pharmacology +16